[Multiple peritrochanteric and pubic calcifications in a young woman on hemodialysis with severe renal osteodystrophy successfully treated with sevelamer+cinacalcet+paracalcitol combination therapy].
Secondary hyperparathyroidism is a frequent complication of chronic renal failure that can induce severe bone disease and negatively influence the cardiovascular outcome. Therefore, nephrologists should attempt to reach the targets recommended by national and international guidelines using all the available therapeutic strategies. We describe the case of a 37-year-old woman affected by spina bifida and myelomeningocele who had been on hemodialysis since 1993. In July 2006 she developed secondary hyperparathyroidism complicated by peritrochanteric calcifications which did not respond to standard therapy. Because it was impossible to perform a parathyroidectomy, we started medical therapy with a combination of sevelamer hydrochloride, paracalcitol and cinacalcet, which resulted in progressive improvement of laboratory data and osteodystrophy. A diagnosis of mixed secondarytertiary hyperparathyroidism was made, but a progressive increase in iPTH to very high levels suggested a rapid evolution toward a pure tertiary form.
Bellotti
G
G
Unita' Operativa di Nefrologia e Dialisi, Azienda Ospedaliera Mater Domini, Cattedra di Nefrologia, Universita' degli Studi, Catanzaro, Italy.
Presta
P
P
Panzino
T
T
Capria
M
M
Caglioti
A
A
Riccio
M
M
Bova
F
F
Fuiano
L
L
Fuiano
G
G
D000328:Adult; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D001847:Bone Diseases / Q000188:drug therapy* / Q000209:etiology*; D002114:Calcinosis / Q000188:drug therapy* / Q000209:etiology*; D002614:Chelating Agents / Q000008:administration & dosage*; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000150:complications* / Q000188:drug therapy*; D000069449:Cinacalcet; D004359:Drug Therapy, Combination; D004872:Ergocalciferols / Q000008:administration & dosage*; D005260:Female; D005269:Femur; D006801:Humans; D009281:Naphthalenes / Q000008:administration & dosage*; D011073:Polyamines / Q000008:administration & dosage*; D011630:Pubic Bone; D012074:Remission Induction; D006435:Renal Dialysis; D000069603:Sevelamer; D012720:Severity of Illness Index
D050071:Bone Density Conservation Agents; D002614:Chelating Agents; D004872:Ergocalciferols; D009281:Naphthalenes; D011073:Polyamines; C084656:paricalcitol; D000069603:Sevelamer; D000069449:Cinacalcet